Gdf2026 Suitability Petitions

Summary

This session provided an overview of the This presentation provided a background refresher on the Generic Drug User Fee Amendments (GDUFA III) Commitment Letter ... This session discussed a risk-based approach to extractables and leachables studies in support of original applications and ... This premier event brings together FDA subject matter experts from every aspect of the pre-ANDA and ANDA assessment ... This session highlighted major deficiencies and other common issues identified during the filing review of ANDAs. The systematic ... This presentation underscored key lessons, address frequently asked questions, and clarify common misunderstandings related ... This presentation highlighted common deficiencies observed in bioequivalence (BE) study designs and explains how they can ... The presentation provided an overview on the U.S. FDA Product-Specific Guidance (PSG) program including how and when ... This presentation focused on strategies to demonstrate bioequivalence of products reformulated due to nitrosamine concerns. This presentation explained the scientific and regulatory rationale underlying key recommendations in PSGs for complex non-oral ...